Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Caribou Biosciences (CRBU) EBIAT (2020 - 2025)

Caribou Biosciences has reported EBIAT over the past 6 years, most recently at -$26.5 million for Q4 2025.

  • Quarterly EBIAT rose 25.36% to -$26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.1 million through Dec 2025, up 0.66% year-over-year, with the annual reading at -$148.1 million for FY2025, 0.66% up from the prior year.
  • EBIAT was -$26.5 million for Q4 2025 at Caribou Biosciences, up from -$27.5 million in the prior quarter.
  • Over five years, EBIAT peaked at -$10.0 million in Q3 2023 and troughed at -$54.1 million in Q2 2025.
  • The 5-year median for EBIAT is -$27.3 million (2022), against an average of -$28.3 million.
  • Year-over-year, EBIAT plummeted 664.48% in 2021 and then soared 62.46% in 2023.
  • A 5-year view of EBIAT shows it stood at -$18.5 million in 2021, then tumbled by 46.05% to -$27.0 million in 2022, then dropped by 27.85% to -$34.5 million in 2023, then fell by 2.85% to -$35.5 million in 2024, then grew by 25.36% to -$26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBIAT are -$26.5 million (Q4 2025), -$27.5 million (Q3 2025), and -$54.1 million (Q2 2025).